Developmental toxicity of artesunate and an artesunate combination in the rat and rabbit
- 22 December 2004
- journal article
- research article
- Published by Wiley in Birth Defects Research Part B: Developmental and Reproductive Toxicology
- Vol. 71 (6) , 380-394
- https://doi.org/10.1002/bdrb.20027
Abstract
The artemisinins are playing an increasingly important role in treating multidrug-resistant malaria. The artemisinin, artesunate, is currently in use in Southeast Asia and is advocated for use in Africa. In these areas, more than one million people die of malaria each year, with the highest mortality occurring in children and pregnant women. To test the developmental toxicity in ICH-compliant animal studies, embryofetal development studies were conducted in rats and rabbits treated with artesunate alone or a three-drug combination (CDA) consisting of chlorproguanil hydrochloride, Dapsone, and artesunate in the ratio 1.00:1.25:2.00. Developmental toxicity seen with CDA could be attributed to the administered dose of artesunate. The hallmark effect of artesunate exposure was a dramatic induction of embryo loss, apparent as abortions in rabbits and resorptions in both rats and rabbits. In addition, low incidences of cardiovascular malformations and a syndrome of skeletal defects were induced at or close to embryolethal doses of artesunate in both rats and rabbits. The cardiovascular malformations consisted of ventricular septal and vessel defects. The skeletal syndrome consisted of shortened and/or bent long bones and scapulae, misshapen ribs, cleft sternebrae, and incompletely ossified pelvic bones. These developmental effects were observed largely in the absence of any apparent maternal toxicity. The no or low adverse effect levels were in the range of 5 to 7 mg/kg/day artesunate. Encouragingly, no adverse drug-related developmental effects have been observed in a limited number of pregnant women (more than 100 first trimester and 600 second and third trimester) treated with artemisinins, primarily artesunate. Investigations of the mechanism of developmental toxicity are ongoing to attempt to determine whether rats and rabbits are more sensitive to artemisinins than humans. Birth Defects Res B 71:380–394, 2004.Keywords
This publication has 35 references indexed in Scilit:
- SB-236057: Critical window of sensitivity study and embryopathy of a potent musculoskeletal teratogenBirth Defects Research Part A: Clinical and Molecular Teratology, 2004
- Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closureBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2003
- Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancyTransactions of the Royal Society of Tropical Medicine and Hygiene, 2001
- Simple and rapid physico-chemical methods to examine action of antimalarial drugs with heminLife Sciences, 2001
- Free Radical Intermediates of Phenytoin and Related TeratogensJournal of Biological Chemistry, 1998
- Malaria Prophylaxis in Pregnancy and ChildrenInfectious Diseases in Clinical Practice, 1996
- Developmental toxicity of mangafodipir trisodium and manganese chloride in Sprague‐Dawley ratsTeratology, 1995
- Species Difference in Developmental Toxicity of an N‐Phenylimide Herbicide between Rats and Rabbits and Sensitive Period of the Toxicity to Rat EmbryosCongenital Anomalies, 1995
- Diflunisal‐induced maternal anemia as a cause of teratogenicity in rabbitsTeratology, 1984
- Forelimb malformation in rats caused by cyclophosphamideActa Orthopaedica, 1984